– Second Quarter 2023 Total Revenue of $38.3 Million; Net Product Revenue for QINLOCK® (ripretinib) Increased 18% to $37.3 Million Compared to Second Quarter 2022 –– Top-line Results for MOTION Pivotal Phase 3 Study of Vimseltinib Expected in Fourth Quarter 2023 –– INSIGHT Pivotal Phase 3 Study of QINLOCK in Second-.
Alberta will pay for a pricey drug that may help ALS patients live longer and better lives : Ottawa Express ottawaxpress.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ottawaxpress.ca Daily Mail and Mail on Sunday newspapers.
Albertans living with ALS, commonly referred to as Lou Gehrig’s Disease, have a new treatment option that can improve their quality of life and help them live longer, and the Alberta government will cover the estimated $18,500 a month per patient.